PIC Therapeutics
Natick
About PIC Therapeutics
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics. PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $40.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2022)
- Website: pictherapeutics.com
- Phone: 6175288715
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pic-therapeutics-8090 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.